The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I found the short five minute video at the link below to be quite informative, in a very simplistic sense. It may be of use to others on this board:
https://www.youtube.com/watch?v=wWBdWMF1XSg
Some people use Malcy's Blog for a second opinion on the company. After yesterday's update, it is encouraging both Malcy and Auctus are keeping their respective target prices at 20p i.e. unchanged.
Let's see how 36-2 production tests, affect their respective target prices in the next few weeks.
From today's RNS:
"At a controlled rate of 2 million square cubic feet of gas per day and 100 barrels of oil per day (an average of 433 barrels of oil equivalent per day) the well flowed continuously and surface flow assurance efforts proved successful."
Wonder what production volumes would make Well 16-2 economically viable. Thoughts and opinions from our more knowledgeable posters would be appreciated.
1981Investor - You really need to get rid of that bee from your bonnet. The majority of people on these bulletin boards have an agenda. When invested we're willing the share price to go up and sometimes share our wildest hopes on here - ramping.
Then when we've sold up, we disappear. Sometimes looking in to reassure ourselves we sold at the peak price, i.e. hoping the price has dropped after we sold.
It's just human nature - no point railing against it.
Thumbs up for yesterday's RNS, but reserve full judgement until a timely Strategic Review is completed and a fair price sale of Cascabel is achieved thereafter.
However, I do also hope it's not too little and too late from an Ecuador government perspective. Otherwise BHP and the likes will be waiting in the wings.